Published: July 2004
Pages: 52
Published by: HTStec

Table of Contents

This report summarizes the results of a comprehensive global Pharma web-based survey on ion channel trends. In particular, it examines through documentation of budgets and number screened the importance of ion channel targets, ion channel selectivity profiling, outsourcing and the potential impact of high throughput electrophysiology (automated patch clamping) on these activities.

Highlights of this Report:

• The survey collected 64 responses (55 complete and 9 partially filled out) from 44 different Pharma/Biotech companies in 2 weeks
• Responses were split geographically approximately 50:50 between North America and Europe.
• Survey respondents were drawn from 31 Big Pharma, 31 Small Pharma/Biotechs, 1 Agrochemical Company and 1 Contract Service Organization.
• Survey respondents represented 33 assay development and primary screening (HTS) labs, 11 hits-to-leads labs, 9 therapeutic area labs, 3 compound profiling labs, 1 secondary screening lab and 9 other lab functions.
• Survey results were expressed as an average of all respondents. In addition, all results were fully reanalyzed after sub-division into the following survey groups: 1) by organization type - Big Pharma; 2) by organization type - Small Pharma/Biotech; 3) by geographic location - North America and 4) by geographic location – Europe.
• The mean number of primary ion channel screens undertaken in 2004 was estimated to be 3.4 screens per year with 416K wells (data points) per screen.
• Globally it was estimated that 742 ion channel primary screens campaigns will be performed in 2004.
• The Pharma market for ion channel primary screening reagents was estimated to be US$30.9Million in 2004, with an annual growth rate of 51%.
• Respondents’ approaches to ion channel selectivity profiling are documented.
• The preferred approach to ion channel profiling chosen by the majority (44%) of survey respondents was to screen selected lead compounds in house against a panel of ion channel targets.
• The Pharma market for ion channel profiling was estimated in 2004 to be US$58.9Million and US$15.7Million for in house and outsourced profiling respectively.
• At least 100X more data points were profiled in house versus outsourced for ion channel profiling in 2004.
• The mean budget allocated per lab for ion channel profiling in 2004 was estimated to be US$270K in house versus US$82K for outsourced profiling.

Purchase report >>